Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The performance of serum biomarkers for the early detection of invasive aspergillosis expectedly depends on the timing of test results relative to the empirical administration of antifungal therapy during neutropenia, although a dynamic evaluation framework is lacking. METHODS: We developed a multi-state model describing simultaneously the likelihood of empirical antifungal therapy and the risk of invasive aspergillosis during neutropenia. We evaluated whether the first positive test result with a biomarker is an independent predictor of invasive aspergillosis when both diagnostic information used to treat and risk factors of developing invasive aspergillosis are taken into account over time. We applied the multi-state model to a homogeneous cohort of 185 high-risk patients with acute myeloid leukemia. Patients were prospectively screened for galactomannan antigenemia twice a week for immediate treatment decision; 2,214 serum samples were collected on the same days and blindly assessed for (1->3)- β-D-glucan antigenemia and a quantitative PCR assay targeting a mitochondrial locus. RESULTS: The usual evaluation framework of biomarker performance was unable to distinguish clinical benefits of β-glucan or PCR assays. The multi-state model evidenced that the risk of invasive aspergillosis is a complex time function of neutropenia duration and risk management. The quantitative PCR assay accelerated the early detection of invasive aspergillosis (P = .010), independently of other diagnostic information used to treat, while β-glucan assay did not (P = .53). CONCLUSIONS: The performance of serum biomarkers for the early detection of invasive aspergillosis is better apprehended by the evaluation of time-varying predictors in a multi-state model. Our results provide strong rationale for prospective studies testing a preemptive antifungal therapy, guided by clinical, radiological, and bi-weekly blood screening with galactomannan antigenemia and a standardized quantitative PCR assay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unemployment Insurance and Unemployment Spells
Meyer, B. D. (1990) · Econometrica · doi:10.2307/2938349 · Cited by 1,178
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354 · cited 2×
“When considering all serum samples collected during study enrollment, the sensitivity of b-glucan (82%) and qPCR (73%) to detect invasive aspergillosis was in the range of pooled estimates (77% [95% CI, 67–84] without difference in the detection of invasive aspergillosis and candidemia [22], and 88% [95% CI, 75–94] [2…”
BackgroundResultAspergillus PCR: One Step Closer to Standardization
White, P. L., Bretagne, S., Klingspor, L., Melchers, W. J. G., McCulloch, E., Schulz, B., Finnstrom, N., Mengoli, C., Barnes, R. A., Donnelly, J. P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-09 · Cited by 296
Self-citationMarchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., & Groups, A. T. E. C. O. I. I. L. (. L. W. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.178 · Cited by 275
Self-citationAlberti, C., Bouakline, A., Ribaud, P., Lacroix, C., Rousselot, P., Leblanc, T., & Derouin, F. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2001.0998 · Cited by 221
Segal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Galactomannan in Bronchoalveolar Lavage for Diagnosing Invasive Fungal Disease
Affolter, K., Tamm, M., Jahn, K., Halter, J., Passweg, J., Hirsch, H. H., & Stolz, D. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0431oc · Cited by 51
Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients
Giacobbe, D. R., Del Bono, V., Viscoli, C., & Mikulska, M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1401467 · Cited by 27
Hammarström, H., Stjärne Aspelund, A., Christensson, B., Heußel, C. P., Isaksson, J., Kondori, N., Larsson, L., Markowicz, P., Richter, J., Wennerås, C., et al. (2018) · Mycoses · doi:10.1111/myc.12773 · Cited by 15
Metadata
- Authors
- Schwarzinger, M., Sagaon-Teyssier, L., Cabaret, O., Bretagne, S., Cordonnier, C., & for the PREVERT Investigators
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-14
- Volume
- 8
- Issue
- 6
- Pages
- e65776
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1989570819
- Cited by
- 35
- References
- 7
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.